Abstract
A case of the neuroleptic malignant syndrome, an idiosyncratic response to neuroleptic drugs, is described. Symptoms persisted for eight weeks. The stopping of neuroleptics and general supportive measures are the mainstay of treatment. Failure to recognise this syndrome can lead to morbidity and death.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Caroff S. N. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980 Mar;41(3):79–83. [PubMed] [Google Scholar]
- Cohen W. J., Cohen N. H. Lithium carbonate, haloperidol, and irreversible brain damage. JAMA. 1974 Dec 2;230(9):1283–1287. [PubMed] [Google Scholar]
- Coons D. J., Hillman F. J., Marshall R. W. Treatment of neuroleptic malignant syndrome with dantrolene sodium: a case report. Am J Psychiatry. 1982 Jul;139(7):944–945. doi: 10.1176/ajp.139.7.944. [DOI] [PubMed] [Google Scholar]
- DELAY J., PICHOT P., LEMPERIERE T., ELISSALDE B., PEIGNE F. [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses]. Ann Med Psychol (Paris) 1960 Jan;118(1):145–152. [PubMed] [Google Scholar]
- Goulon M., de Rohan-Chabot P., Elkharrat D., Gajdos P., Bismuth C., Conso F. Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases. Neurology. 1983 Apr;33(4):516–518. [PubMed] [Google Scholar]
- Smego R. A., Jr, Durack D. T. The neuroleptic malignant syndrome. Arch Intern Med. 1982 Jun;142(6):1183–1185. [PubMed] [Google Scholar]